Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Anti-diabetic Drug Metformin: Challenges and Perspectives for Cancer Therapy

Author(s): Kaniyampadi S. Snima, Prathesha Pillai, Aleena M. Cherian, Shantikumar V. Nair and Vinoth-Kumar Lakshmanan

Volume 14, Issue 8, 2014

Page: [727 - 736] Pages: 10

DOI: 10.2174/1568009614666141020105502

Price: $65

Abstract

Metformin, a biguanide, is a commonly administered drug for the management of type 2 diabetes mellitus. The drug received tremendous recognition, when retrospective studies proved metformin-associated reduction in cancer risk. Metformin has potential anticancer effects and an ability to suppress tumor growth both in vitro and in vivo. Activation of LKB1/AMPK pathway and cancer stem cell destruction along with cell cycle arrest and apoptosis induction are the proposed mechanisms of anticancer potential of metformin. Nanotechnology approaches have also been adopted for metformin delivery to cancer cells. This review directs on the application of metformin for the therapy of various cancers and also the different pathways responsible for the metformin derived anticancer effect. It also focuses on the pharmacological applications of metformin and the nanotechnology approaches for metformin delivery.

Keywords: Breast cancer, endometrial cancer, metformin, nanotechnology, prostate cancer, ovarian cancer, pancreatic cancer, pathways.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy